Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock.
Septic shock is the most severe form of sepsis. It is widely accepted that cytokines play pivotal roles in the pathophysiology of septic shock. We reported previously that continuous hemodiafiltration (CHDF) using a polymethylmethacrylate (PMMA) membrane hemofilter removed various cytokines from blood continuously and efficiently, mainly by adsorption to membrane matrix of the hemofilter. Furthermore, in April 2000, we introduced to clinical practice a rapid assay system that determines blood levels of IL (interleukin)-6 in approximately 30 min. This enabled us to routinely measure blood IL-6 as an index of cytokine cascade activation in critically ill patients for real-time clinical monitoring of hypercytokinemia. The aim of the present cohort study was to evaluate the clinical efficacy of PMMA-CHDF in septic shock, a typical condition associated with hypercytokinemia. Forty-three patients with septic shock were assessed by monitoring of blood IL-6 level with a rapid assay system and immediate initiation of critical care including PMMA-CHDF for cytokine removal. Following initiation of PMMA-CHDF, early improvement of hemodynamics was noted, as well as an increase in urine output. PMMA-CHDF treatment improved both hypercytokinemia (assessed by measurement of blood IL-6 level) and dysoxia (assessed by measurement of blood lactate level). The present findings suggest that cytokine-oriented critical care using PMMA-CHDF might be an effective strategy for the treatment of septic shock.
Nakada
Taka-Aki
TA
Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, 260-8677, Japan. taka.nakada@nifty.com
Oda
Shigeto
S
Matsuda
Ken-Ichi
K
Sadahiro
Tomohito
T
Nakamura
Masataka
M
Abe
Ryuzo
R
Hirasawa
Hiroyuki
H
D000368:Aged; D001794:Blood Pressure; D015331:Cohort Studies; D005260:Female; D006339:Heart Rate; D017583:Hemodiafiltration / Q000379:methods*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D019904:Polymethyl Methacrylate; D012772:Shock, Septic / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
D015850:Interleukin-6; D019904:Polymethyl Methacrylate